Replies to post #480489 on Anavex Life Sciences Corp (AVXL)

[Hosai]

The curve would be nice to see, we would hope the original placebo group beat the expected deterioration.
However original dosed beating original placebo even more over time is the number 1 finding an OLE can have imo. Especially with the effect size getting so much larger and p size smaller towards 192 weeks. It's harder to poke holes in this type of analysis than with a look at "absolute" numbers where critics would say "you can't make cross comparisons with other trials."
However clearly though it would be better if original placebo have deteriorated less than expected. As stated before though by the start of OLE they would have averaged 74-75 years old with MMSEs around 22 so about to enter early moderate AD. Unforuntately likely harder for these patients to be helped as much by an AD drug.

[WilliamMunny]

Yes, the Phase 2 Schizophrenia is a small trial, but I was encouraged that they have decided to enlarge it so it can be better powered.

[boi568]

With all the ground Missling had to cover today, I wouldn't jump to the conclusion that a missing OLE graph implies no further good news. We will know in April.

[imho]

"Without longitudinal charts for the OLE endpoints, it leaves open the possibility that there was no absolute improvement in trajectory for early cohort's ADL, just relative separation between cohorts. Let's see if we get a clearer picture at the PD/AD conf, though I suspect it's not coming."

Let's say that "there was no absolute improvement in trajectory for early cohort's ADL, just relative separation between cohorts" is true and the company does not present data to the contrary. How important is that, to you, relative to the Mab's performance as you know it? How important do you think, it is to the EMA? TIA.

IMHO